ESMO - Eur. Oncology

What were the key advances in #BreastCancer at #ESMO26?
Follow the final ESMO Congress Highlights webinar on 13 Nov, 18:30 CET.
Chaired by Seock-Ah Im, featuring Hope Rugo and Janice Tsang, with highlights from KEYNOTE-B49, PANKU-Breast01, the NATALEE 6-year follow-up and an AI digital pathology study.
➡️ow.ly/WcrV5103ES7

🤖 #ESMOAI26: AI is transforming clinical trials. Explore how AI can improve efficiency, patient recruitment, and trial design in oncology research.

Register now and meet us in Berlin, and online.
🔗 ow.ly/H5Wl5100phE

#esmomeetings

@fleouay @DanielTruhn @PrelajArsela @dbittermanmd @jnkath

The growing role of biomarkers in #oncology emphasises the importance of frameworks that support their evaluation and clinical application.

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S) establishes the minimum requirements for a molecular-guided treatment to have tumour-agnostic potential.
🔗 ow.ly/GMty51047Iq
@FAndreMD

👉 Dr. Sandra D'Angelo, New York, USA, is looking for research that helps crack the code of immune resistance in sarcoma. Could your work be the next step forward for patients? Submit your abstract by 24 November.

🔗 ow.ly/guch5100oml

#ESMORareCancers27 #esmomeetings

What were the key advances in melanoma and sarcoma at #ESMO26?
Follow the ESMO Congress Highlights webinar on 12 Nov, 18:30 CET.
Chaired by Robin Jones, featuring Sapna Patel and Joanna Szkandera, with insights from INTerpath-001, ARTEMIS-011, TANGENT and more, followed by a live Q&A.
ow.ly/kx5u5103ENc
@RobinL_Jones @DrSapnaPatel